ABSTRACT
Background: The International Association for Study of pain, has defined pain as actual or potential tissue damage or described in terms of such damage. But the burden of unwanted side effects with current regimens are high. To explore the potential of Ayurveda drugs, this study is done by using Origanum vulgare.Methods: In vivo model used-Hot plate method. Origanum vulgare (84 mg/kg p.o) was administered in mice. The analgesic activity was studied by recording the reaction time after administration of the drug at frequent intervals up to 3 hrs. The results were analysed by ANOVA and Tukey’s test. P value <0.05 was considered as significant. Pentazocine showed statistically prolongation in the reaction time after 30 min as compared to Origanum vulgare.Results: In hot plate method, pentazocine showed statistically significant increase in the reaction time after 30 min of administration as compared to control group. However, Origanum vulgare in a dose of 84 mg/kg showed significantly increase in the reaction time after 30 min of administration as compared to control group. On comparing pentazocine and Origanum vulgare, pentazocine showed highly significant increase in the reaction time after 30 min as compared to Origanum vulgare at 84 mg/kg dose.Conclusions: From the present study, it was concluded that extract of Origanum vulgare exerted analgesic activity in both the models. However, it was less potent than pentazocine. Thus, Origanum vulgare can be used in mild to moderate painful conditions.
ABSTRACT
Background: As of 2018, 2.1 billion people nearly 30% of the world’s population are either obese or overweight. Worldwide obesity has nearly tripled since 1975. It is an emerging health problem with major adverse effects on health. It is a risk factor for many chronic diseases but is best known for its role in metabolic syndrome, which can lead to type 2 diabetes mellitus as well as cardiovascular diseases. Anti-obesity drugs are available but have many side effects. Voglibose, an antidiabetic drug, is an alpha glucosidase inhibitor which shows promising results in the reduction of body weight with minimal side effects.Methods: Voglibose (7 mg/kg) was administered to rats fed with normal laboratory chows and high fat diet to see its effect on body weight, body mass index, abdominal and thoracic circumference, and lipid profile at the end of 12 weeks.Results: Administration of voglibose significantly reduced food consumption, feed efficiency and increase in body weight induced by high fat diet in rats. Rats fed on normal diet also showed reductions in the same parameters, suggesting its weight lowering effect. Reductions in the anthropometric measurements, hypolipidemic effects and glucose lowering effects were also observed.Conclusions: Voglibose prevented high fat diet-induced obesity and improvement in metabolic profile, which ultimately has systemic effects on body weight in rats. Further studies are needed to see its potential therapeutic use in obese patients with type 2 diabetes mellitus, and related complications.